FRINK Linked Data Fragments server

Matches in SemOpenAlex for { <https://semopenalex.org/work/W2560219063> ?p ?o ?g. }

• W2560219063 endingPage "436" @default.
• W2560219063 startingPage "426" @default.
• W2560219063 abstract "While vascular endothelial growth factor-targeted therapy and mammalian target of rapamycin inhibition are effective strategies in treating clear cell renal cell carcinoma (ccRCC), the most effective therapeutic approach for patients with non-clear cell RCC (non-ccRCC) is unknown. To systematically review relevant literature comparing the oncological outcomes and adverse events of different systemic therapies for patients with metastatic non-ccRCC. Relevant databases including MEDLINE, Embase, and the Cochrane Library were searched up to March 24, 2016. Only comparative studies were included. Risk of bias and confounding assessments were performed. A meta-analysis was planned for and only performed if methodologically appropriate; otherwise, a narrative synthesis was undertaken. The literature search identified 812 potential titles and abstracts. Five randomized controlled trials, recruiting a total of 365 patients, were included. Three studies compared sunitinib against everolimus, one of which reported the results for non-ccRCC as a subgroup rather than as an entire randomized cohort. Individually, the studies showed a trend towards favoring sunitinib in terms of overall survival and progression-free survival (PFS; Everolimus versus Sunitinib in Patients with Metastatic Non-clear Cell Renal Cell Carcinoma hazard ratio [HR]: 1.41, 80% confidence interval [CI] 1.03–1.92 and 1.41, 95% CI: 0.88–2.27, Evaluation in Metastatic Non-clear Cell Renal Cell Carcinoma HR: 1.16, 95% CI: 0.67–2.01, Efficacy and Safety Comparison of RAD001 Versus Sunitinib in the First-line and Second-line Treatment of Patients with Metastatic Renal Cell Carcinoma HR: 1.5, 95% CI: 0.9–2.8), but this trend did not reach statistical significance in any study. Meta-analysis was performed on two studies which solely recruited patients with non-ccRCC reporting on PFS, the results of which were inconclusive (HR: 1.30, 95% CI: 0.91–1.86). Sunitinib was associated with more Grade 3–4 adverse events than everolimus, although this was not statistically significant. This systematic review and meta-analysis represent a robust summary of the evidence base for systemic treatment of metastatic non-ccRCC. The results show a trend towards favoring vascular endothelial growth factor-targeted therapy for PFS and overall survival compared with mammalian target of rapamycin inhibitors, although statistical significance was not reached. The relative benefits and harms of these treatments remain uncertain. Further research, either in the form of an individual patient data meta-analysis involving all relevant trials, or a randomized controlled trial with sufficient power to detect potential differences between treatments, is needed. We examined the literature to determine the most effective treatments for advanced kidney cancer patients whose tumors are not of the clear cell subtype. The results suggest that a drug called sunitinib might be more effective than everolimus, but the statistics supporting this statement are not yet entirely reliable. Further research is required to clarify this unmet medical need." @default.
• W2560219063 created "2016-12-16" @default.
• W2560219063 creator A5008870382 @default.
• W2560219063 creator A5010457951 @default.
• W2560219063 creator A5012800133 @default.
• W2560219063 creator A5016971686 @default.
• W2560219063 creator A5018595176 @default.
• W2560219063 creator A5029542738 @default.
• W2560219063 creator A5030488677 @default.
• W2560219063 creator A5034370196 @default.
• W2560219063 creator A5042581048 @default.
• W2560219063 creator A5046215402 @default.
• W2560219063 creator A5061266716 @default.
• W2560219063 creator A5062834106 @default.
• W2560219063 creator A5068678186 @default.
• W2560219063 creator A5074162105 @default.
• W2560219063 creator A5075971703 @default.
• W2560219063 creator A5080116321 @default.
• W2560219063 creator A5091711650 @default.
• W2560219063 creator A5091833311 @default.
• W2560219063 date "2017-03-01" @default.
• W2560219063 modified "2023-10-18" @default.
• W2560219063 title "A Systematic Review and Meta-analysis Comparing the Effectiveness and Adverse Effects of Different Systemic Treatments for Non-clear Cell Renal Cell Carcinoma" @default.
• W2560219063 cites W1544119899 @default.
• W2560219063 cites W1754265771 @default.
• W2560219063 cites W2010991736 @default.
• W2560219063 cites W2020599136 @default.
• W2560219063 cites W2037716205 @default.
• W2560219063 cites W2063698832 @default.
• W2560219063 cites W2068059571 @default.
• W2560219063 cites W2074416418 @default.
• W2560219063 cites W2106602966 @default.
• W2560219063 cites W2111867681 @default.
• W2560219063 cites W2116095691 @default.
• W2560219063 cites W2135400982 @default.
• W2560219063 cites W2146810218 @default.
• W2560219063 cites W2164317031 @default.
• W2560219063 cites W2173523195 @default.
• W2560219063 cites W2233483325 @default.
• W2560219063 cites W2235523093 @default.
• W2560219063 cites W3022903699 @default.
• W2560219063 doi "https://doi.org/10.1016/j.eururo.2016.11.020" @default.
• W2560219063 hasPubMedId "https://pubmed.ncbi.nlm.nih.gov/27939075" @default.
• W2560219063 hasPublicationYear "2017" @default.
• W2560219063 type Work @default.
• W2560219063 sameAs 2560219063 @default.
• W2560219063 citedByCount "107" @default.
• W2560219063 countsByYear W25602190632017 @default.
• W2560219063 countsByYear W25602190632018 @default.
• W2560219063 countsByYear W25602190632019 @default.
• W2560219063 countsByYear W25602190632020 @default.
• W2560219063 countsByYear W25602190632021 @default.
• W2560219063 countsByYear W25602190632022 @default.
• W2560219063 countsByYear W25602190632023 @default.
• W2560219063 crossrefType "journal-article" @default.
• W2560219063 hasAuthorship W2560219063A5008870382 @default.
• W2560219063 hasAuthorship W2560219063A5010457951 @default.
• W2560219063 hasAuthorship W2560219063A5012800133 @default.
• W2560219063 hasAuthorship W2560219063A5016971686 @default.
• W2560219063 hasAuthorship W2560219063A5018595176 @default.
• W2560219063 hasAuthorship W2560219063A5029542738 @default.
• W2560219063 hasAuthorship W2560219063A5030488677 @default.
• W2560219063 hasAuthorship W2560219063A5034370196 @default.
• W2560219063 hasAuthorship W2560219063A5042581048 @default.
• W2560219063 hasAuthorship W2560219063A5046215402 @default.
• W2560219063 hasAuthorship W2560219063A5061266716 @default.
• W2560219063 hasAuthorship W2560219063A5062834106 @default.
• W2560219063 hasAuthorship W2560219063A5068678186 @default.
• W2560219063 hasAuthorship W2560219063A5074162105 @default.
• W2560219063 hasAuthorship W2560219063A5075971703 @default.
• W2560219063 hasAuthorship W2560219063A5080116321 @default.
• W2560219063 hasAuthorship W2560219063A5091711650 @default.
• W2560219063 hasAuthorship W2560219063A5091833311 @default.
• W2560219063 hasBestOaLocation W25602190632 @default.
• W2560219063 hasConcept C126322002 @default.
• W2560219063 hasConcept C143998085 @default.
• W2560219063 hasConcept C168563851 @default.
• W2560219063 hasConcept C197934379 @default.
• W2560219063 hasConcept C207103383 @default.
• W2560219063 hasConcept C2776478404 @default.
• W2560219063 hasConcept C2777472916 @default.
• W2560219063 hasConcept C2779490328 @default.
• W2560219063 hasConcept C2779699572 @default.
• W2560219063 hasConcept C2781068499 @default.
• W2560219063 hasConcept C2781278892 @default.
• W2560219063 hasConcept C44249647 @default.
• W2560219063 hasConcept C71924100 @default.
• W2560219063 hasConcept C95190672 @default.
• W2560219063 hasConceptScore W2560219063C126322002 @default.
• W2560219063 hasConceptScore W2560219063C143998085 @default.
• W2560219063 hasConceptScore W2560219063C168563851 @default.
• W2560219063 hasConceptScore W2560219063C197934379 @default.
• W2560219063 hasConceptScore W2560219063C207103383 @default.
• W2560219063 hasConceptScore W2560219063C2776478404 @default.
• W2560219063 hasConceptScore W2560219063C2777472916 @default.
• W2560219063 hasConceptScore W2560219063C2779490328 @default.
• W2560219063 hasConceptScore W2560219063C2779699572 @default.
• W2560219063 hasConceptScore W2560219063C2781068499 @default.

• next